Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma
4th approved indication for toripalimab SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi…
Novee Launches Agentic Fix to Turn Validated Exploits into Implemented Fixes
The AI Search Shift: A Survival Guide for CMOs, PR Professionals, and Website Managers
An Architectural Approach to Solving Prompt Security Challenges
Optical Networking At Micro Scale